Shilpa Medicare Arm Secures 30.4% Stake in Spanish Biotechnology Firm for EUR7 Million

MT Newswires Live06-03 14:17

Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare (NSE:SHILPAMED, BOM:530549), has agreed to acquire a 30.4% stake in Spanish biotechnology company Gate2Brain for 7 million euros, according to a Wednesday filing to the Indian stock exchanges.

Under the terms of the agreement, Shilpa will become a strategic shareholder of Gate2Brain and its dedicated chemistry, manufacturing, and controls (CMC), and regulatory partner for G2B-002 - Gate2Brain's lead program in brain cancer.

Gate2Brain is in the pre-clinical stage of product development currently for G2B-002, which has been granted Orphan Drug Designation by both the US Food and Drug Administration and the European Medicines Agency.

The company's shares were down over 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640762969?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 14:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640762969","market":"us","top_or_hot":-1,"title":"Shilpa Medicare Arm Secures 30.4% Stake in Spanish Biotechnology Firm for EUR7 Million","media":"MT Newswires Live","content":"<html><body><p> Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare (NSE:SHILPAMED, BOM:530549), has agreed to acquire a 30.4% stake in Spanish biotechnology company Gate2Brain for 7 million euros, according to a Wednesday filing to the Indian stock exchanges.</p><p>Under the terms of the agreement, Shilpa will become a strategic shareholder of Gate2Brain and its dedicated chemistry, manufacturing, and controls (CMC), and regulatory partner for G2B-002 - Gate2Brain's lead program in brain cancer.</p><p>Gate2Brain is in the pre-clinical stage of product development currently for G2B-002, which has been granted Orphan Drug Designation by both the US Food and Drug Administration and the European Medicines Agency.</p><p>The company's shares were down over 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shilpa Medicare Arm Secures 30.4% Stake in Spanish Biotechnology Firm for EUR7 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShilpa Medicare Arm Secures 30.4% Stake in Spanish Biotechnology Firm for EUR7 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-03 14:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare (NSE:SHILPAMED, BOM:530549), has agreed to acquire a 30.4% stake in Spanish biotechnology company Gate2Brain for 7 million euros, according to a Wednesday filing to the Indian stock exchanges.</p><p>Under the terms of the agreement, Shilpa will become a strategic shareholder of Gate2Brain and its dedicated chemistry, manufacturing, and controls (CMC), and regulatory partner for G2B-002 - Gate2Brain's lead program in brain cancer.</p><p>Gate2Brain is in the pre-clinical stage of product development currently for G2B-002, which has been granted Orphan Drug Designation by both the US Food and Drug Administration and the European Medicines Agency.</p><p>The company's shares were down over 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B1BXHZ80.USD","symbol_name":"Legg Mason ClearBridge - US Appreciation A Acc USD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640762969","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640762969","pubTimestamp":1780467467,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare , has agreed to acquire a 30.4% stake in Spanish biotechnology company Gate2Brain for 7 million euros, according to a Wednesday filing to the Indian stock exchanges.Under the terms of the agreement, Shilpa will become a strategic shareholder of Gate2Brain and its dedicated chemistry, manufacturing, and controls , and regulatory partner for G2B-002 - Gate2Brain's lead program in brain cancer.Gate2Brain is in the pre-clinical stage of product development currently for G2B-002, which has been granted Orphan Drug Designation by both the US Food and Drug Administration and the European Medicines Agency.The company's shares were down over 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","BK4006":"钢铁","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","CMC":"美国工商五金公司","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0971096721.USD":"富达环球金融服务 A","LU0149725797.USD":"汇丰美国股市经济规模基金","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0882574139.USD":"富达环球消费行业基金A ACC"},"translate_title":"Shilpa Medicare部门以700万欧元收购西班牙生物技术公司30.4%的股份","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMC":1},"content_text":"Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare (NSE:SHILPAMED, BOM:530549), has agreed to acquire a 30.4% stake in Spanish biotechnology company Gate2Brain for 7 million euros, according to a Wednesday filing to the Indian stock exchanges.Under the terms of the agreement, Shilpa will become a strategic shareholder of Gate2Brain and its dedicated chemistry, manufacturing, and controls (CMC), and regulatory partner for G2B-002 - Gate2Brain's lead program in brain cancer.Gate2Brain is in the pre-clinical stage of product development currently for G2B-002, which has been granted Orphan Drug Designation by both the US Food and Drug Administration and the European Medicines Agency.The company's shares were down over 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640762969","isCrawlerRequest":true}